Wayne A. Cass
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Wayne A. Cass has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Laura E. Peters
Department of Neuroscience, University of Kentucky College of Medicine, Lexington, KY, USA
9 shared publicationsMichael P. Smith
Department of Anatomy and Neurobiology, MN-225 Chandler Medical Center, University of Kentucky College of Medicine, Lexington, Kentucky 40536-0298, USA
4 shared publicationsDavid M. Yurek
Department of Anatomy and Neurobiology, MN-225 Chandler Medical Center, University of Kentucky College of Medicine, Lexington, USA
3 shared publicationsAnita M. Fletcher
Department of Neurosurgery, University of Kentucky College of Medicine, Lexington, USA
2 shared publicationsAnders H. Andersen
1 shared publicationAnita Fletcher-Turner
University of Kentucky College of Medicine
1 shared publication
Latest Publications
- 1 August 2023
- Published by Elsevier in Neurochemistry International
- Vol. 169, 105590
Calcitriol protects against reductions in striatal serotonin in rats treated with neurotoxic doses of methamphetamine
- 1 August 2023
- Published by Elsevier in Neurochemistry International
- Vol. 169, 105590
Calcitriol protects against reductions in striatal serotonin in rats treated with neurotoxic doses of methamphetamine
- Open Access
- 1 September 2017
- Published by Elsevier in Neurochemistry International
- Vol. 108, 222-229
Reduced ability of calcitriol to promote augmented dopamine release in the lesioned striatum of aged rats
- 1 September 2017
- Published by Elsevier in Neurochemistry International
- Vol. 108, 222-229
Open AccessReduced ability of calcitriol to promote augmented dopamine release in the lesioned striatum of aged rats
- 25 May 2014
- Published by Springer Nature in Neurochemical Research
- Vol. 39 (8) , 1467-1476
Calcitriol Promotes Augmented Dopamine Release in the Lesioned Striatum of 6-Hydroxydopamine Treated Rats
Current therapies for Parkinson’s disease (PD) offer symptomatic relief but do not provide a cure or slow the disease process. Treatments that could halt progression of the disease or help restore function to damaged neurons would be of substantial benefit. Calcitriol, the active metabolite of vitamin D, has been shown to have significant effects on the brain. These effects include upregulating trophic factor levels, and reducing the severity of some central nervous system lesions. While previous studies have shown that calcitriol can be neuroprotective in 6-hydroxydopamine (6-OHDA) rodent models of PD, the present experiments were designed to examine the ability of calcitriol to promote restoration of extracellular dopamine (DA) levels and tissue content of DA in animals previously lesioned with 6-OHDA. Male Fischer-344 rats were given a single injection of 12 µg 6-OHDA into the right striatum. Four weeks later the animals were administered vehicle or calcitriol (0.3 or 1.0 µg/kg, s.c.) once a day for eight consecutive days. Three weeks after the calcitriol treatments in vivo microdialysis experiments were conducted to measure potassium and amphetamine evoked overflow of DA from both the left and right striata. In control animals treated with 6-OHDA and vehicle there were significant reductions in both potassium and amphetamine evoked overflow of DA on the lesioned side of the brain compared to the contralateral side. In animals treated with 6-OHDA followed by calcitriol there was significantly greater potassium and amphetamine evoked overflow of DA from the lesioned striatum compared to that from the control animals. The calcitriol treatments also led to increases in postmortem tissue levels of DA in the striatum and substantia nigra. These results suggest that calcitriol may help promote recovery of dopaminergic functioning in injured nigrostriatal neurons.
- 25 May 2014
- Published by Springer Nature in Neurochemical Research
- Vol. 39 (8) , 1467-1476
Calcitriol Promotes Augmented Dopamine Release in the Lesioned Striatum of 6-Hydroxydopamine Treated Rats
Current therapies for Parkinson’s disease (PD) offer symptomatic relief but do not provide a cure or slow the disease process. Treatments that could halt progression of the disease or help restore function to damaged neurons would be of substantial benefit. Calcitriol, the active metabolite of vitamin D, has been shown to have significant effects on the brain. These effects include upregulating trophic factor levels, and reducing the severity of some central nervous system lesions. While previous studies have shown that calcitriol can be neuroprotective in 6-hydroxydopamine (6-OHDA) rodent models of PD, the present experiments were designed to examine the ability of calcitriol to promote restoration of extracellular dopamine (DA) levels and tissue content of DA in animals previously lesioned with 6-OHDA. Male Fischer-344 rats were given a single injection of 12 µg 6-OHDA into the right striatum. Four weeks later the animals were administered vehicle or calcitriol (0.3 or 1.0 µg/kg, s.c.) once a day for eight consecutive days. Three weeks after the calcitriol treatments in vivo microdialysis experiments were conducted to measure potassium and amphetamine evoked overflow of DA from both the left and right striata. In control animals treated with 6-OHDA and vehicle there were significant reductions in both potassium and amphetamine evoked overflow of DA on the lesioned side of the brain compared to the contralateral side. In animals treated with 6-OHDA followed by calcitriol there was significantly greater potassium and amphetamine evoked overflow of DA from the lesioned striatum compared to that from the control animals. The calcitriol treatments also led to increases in postmortem tissue levels of DA in the striatum and substantia nigra. These results suggest that calcitriol may help promote recovery of dopaminergic functioning in injured nigrostriatal neurons.
- 31 January 2012
- Published by Elsevier in Neurochemistry International
- Vol. 60 (2) , 186-191
Evoked dopamine overflow is augmented in the striatum of calcitriol treated rats
- 31 January 2012
- Published by Elsevier in Neurochemistry International
- Vol. 60 (2) , 186-191
Evoked dopamine overflow is augmented in the striatum of calcitriol treated rats
- 1 November 2010
- Published by Elsevier in Neurochemistry International
- Vol. 57 (5) , 540-546
Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum
- 1 November 2010
- Published by Elsevier in Neurochemistry International
- Vol. 57 (5) , 540-546
Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum
- 30 January 2010
- Published by Springer Nature in Neurochemical Research
- Vol. 35 (5) , 727-734
Neurturin Effects on Nigrostriatal Dopamine Release and Content: Comparison with GDNF
Neurturin (NTN) is a member of the glial cell line-derived neurotrophic factor (GDNF) family; and, while GDNF has been shown to increase dopamine (DA) release in normal animals, the ability of NTN to alter DA release has not been previously reported. The purpose of the present study was to determine if NTN could alter striatal DA release, and to compare the effects of NTN to GDNF. Male Fischer-344 rats were given a single injection of vehicle or 5 μg NTN or GDNF into the right substantia nigra. Three weeks later microdialysis experiments were conducted to assess striatal DA release. Basal extracellular levels of striatal DA were not affected by either NTN or GDNF. However, both NTN and GDNF led to increases in amphetamine-evoked overflow of DA from the ipsilateral striatum, and there was a trend for potassium-evoked overflow to be augmented. Postmortem tissue levels of DA were decreased by approximately 20% in the striatum, and increased by approximately 100% in the substantia nigra, on the ipsilateral side of the brain compared to the contralateral side following both NTN and GDNF injection. Thus, NTN, like GDNF, can augment striatal DA release, and the magnitude of the NTN effects are similar to those of GDNF.
- 30 January 2010
- Published by Springer Nature in Neurochemical Research
- Vol. 35 (5) , 727-734
Neurturin Effects on Nigrostriatal Dopamine Release and Content: Comparison with GDNF
Neurturin (NTN) is a member of the glial cell line-derived neurotrophic factor (GDNF) family; and, while GDNF has been shown to increase dopamine (DA) release in normal animals, the ability of NTN to alter DA release has not been previously reported. The purpose of the present study was to determine if NTN could alter striatal DA release, and to compare the effects of NTN to GDNF. Male Fischer-344 rats were given a single injection of vehicle or 5 μg NTN or GDNF into the right substantia nigra. Three weeks later microdialysis experiments were conducted to assess striatal DA release. Basal extracellular levels of striatal DA were not affected by either NTN or GDNF. However, both NTN and GDNF led to increases in amphetamine-evoked overflow of DA from the ipsilateral striatum, and there was a trend for potassium-evoked overflow to be augmented. Postmortem tissue levels of DA were decreased by approximately 20% in the striatum, and increased by approximately 100% in the substantia nigra, on the ipsilateral side of the brain compared to the contralateral side following both NTN and GDNF injection. Thus, NTN, like GDNF, can augment striatal DA release, and the magnitude of the NTN effects are similar to those of GDNF.
- 1 October 2007
- Vol. 57 (5) , 487-92
Fenbendazole treatment may influence lipopolysaccharide effects in rat brain.
In evaluating discrepant results between experiments in our laboratory, we collected data that challenge the notion that anthelminthic drugs like FBZ do not alter inflammatory responses. We found that FBZ significantly modulates inflammation in F344 rats intrastriatally injected with LPS. FBZ treatment of LPS-injected rats significantly increased weight loss, microglial activation, and dopamine loss; in addition, FBZ attenuated the LPS-induced loss of astrocytes. Therefore, FBZ treatment altered the effects of LPS injection. Caution should be used in interpreting data collected from rats treated with LPS and FBZ.
- 1 October 2007
- Vol. 57 (5) , 487-92
Fenbendazole treatment may influence lipopolysaccharide effects in rat brain.
In evaluating discrepant results between experiments in our laboratory, we collected data that challenge the notion that anthelminthic drugs like FBZ do not alter inflammatory responses. We found that FBZ significantly modulates inflammation in F344 rats intrastriatally injected with LPS. FBZ treatment of LPS-injected rats significantly increased weight loss, microglial activation, and dopamine loss; in addition, FBZ attenuated the LPS-induced loss of astrocytes. Therefore, FBZ treatment altered the effects of LPS injection. Caution should be used in interpreting data collected from rats treated with LPS and FBZ.
- 1 February 2007
- Published by Elsevier in Neurobiology of Aging
- Vol. 28 (2) , 258-271
Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys
- 1 February 2007
- Published by Elsevier in Neurobiology of Aging
- Vol. 28 (2) , 258-271
Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys
- 1 February 2007
- Published by Elsevier in Neuroscience
- Vol. 144 (3) , 1057-1066
Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson’s disease
- 1 February 2007
- Published by Elsevier in Neuroscience
- Vol. 144 (3) , 1057-1066
Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson’s disease
- 1 February 2007
- Published by Elsevier in Neuroscience Letters
- Vol. 412 (3) , 259-263
GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease
- 1 February 2007
- Published by Elsevier in Neuroscience Letters
- Vol. 412 (3) , 259-263
GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease